Eisai's Halaven misses in earlier breast cancer indication

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) said breast cancer drug Halaven eribulin mesylate missed the co-primary endpoints in a Phase III trial evaluating the product as an earlier line of therapy than...